Insight into interleukin-37: The potential therapeutic target in allergic diseases

Huang, Zhaofeng; Xie, Lihui; Li, He; Liu, Xiuxing; Bellanti, Joseph A.; Zheng, Song Guo; Su, Wenru

doi:10.1016/j.cytogfr.2019.10.003

Cited by 13 publications

(10 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have reported the significant role of IL-37 in human inflammatory diseases 10–13 19. Yang et al demonstrated that IL-37 increases in patients with rheumatoid arthritis and is positively associated with disease progression 20.…”

Section: Discussionmentioning

confidence: 99%

“…9 Recent studies have reported the significant role of IL-37 in human inflammatory diseases such as chronic periodontitis, lupus erythematosus, allergy, rheumatoid arthritis, Behçet's disease, and acute coronary syndrome. [10][11][12][13][14][15] Based on the above, the aim of this study was to compare the serum levels of IL-37 in patients with CAD compared with the control group, its correlation with serum levels of inflammatory cytokines (IL-6, TNF-α, and IL-32), highsensitivity C reactive protein (hs-CRP), oxidative stress markers (oxidized LDL (ox-LDL), ferric-reducing antioxidant power assay (FRAP), and malondialdehyde (MDA)) as well as ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) gene expression in peripheral blood mononuclear cell (PBMCs) of patients with CAD.…”

Section: Original Researchmentioning

confidence: 99%

See 1 more Smart Citation

Serum Levels of IL-37 and Correlation with Inflammatory Cytokines and Clinical Outcomes in Patients with Coronary Artery Disease

Rafiei

Ahmadi

Kazemian

et al. 2022

Journal of Investigative Medicine

View full text Add to dashboard Cite

Coronary artery disease (CAD) due to atherosclerosis is one of the important reasons for death worldwide. Recent evidence has suggested the essential role of inflammation in the progression of atherosclerosis. Interleukin (IL)-37 is a critical anti-inflammatory member of the IL-1 family which regulates the inflammatory processes. The aim of this study was to compare the serum levels of IL-37 in patients with CAD compared with the control group and its correlation with oxidative stress, cholesterol homeostasis, and inflammation in patients with CAD. A total of 42 patients with CAD and 42 sex-matched and age- matched controls who underwent coronary angiography were included in this study. The serum levels of IL-37 were evaluated via ELISA. Serum levels of biochemical risk factors were determined by enzymatic methods. Serum levels of IL-37 in the CAD group subjects were significantly lower than in the control group and IL-37 was significantly increased in men with CAD than in women with CAD. IL-37 significantly had an inverse correlation with IL-6, tumor necrosis factor-α, IL-32, high-sensitivity C reactive protein, oxidized low-density lipoprotein, and malondialdehyde. Also, IL-37 had a significantly positive correlation with ferric-reducing antioxidant power (FRAP) assay. In addition, IL-37 has positively correlated with ATP-binding cassette transporter A1 and G1 gene expression in peripheral blood mononuclear cells and serum levels of the FRAP. A receiver operating characteristic test displayed that IL-37 level ratios were a relatively significant CAD predictor. Our results indicated that decreased serum levels of IL-37 in patients with CAD and its relationship with inflammatory cytokines and reverse cholesterol transport genes are more likely to be associated in the inflammatory process with disease pathology.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Original Researchmentioning

confidence: 99%

Serum Levels of IL-37 and Correlation with Inflammatory Cytokines and Clinical Outcomes in Patients with Coronary Artery Disease

Rafiei

Ahmadi

Kazemian

et al. 2022

Journal of Investigative Medicine

View full text Add to dashboard Cite

show abstract

“…Intracellularly, IL-37b was cleaved and activated by caspase-1 and formed mothers against decapentaplegic homolog 3 (Smad3) in the nucleus. Extracellularly, IL-37b transduces anti-inflammatory signals by forming IL-37/ IL1R8/IL-18Rα complex [13][14][15]. Several studies demonstrated that IL-37b could downregulate IL-17 and IL-4 secretion by CD4+ T cells through interacting with IL1R8 in AR [16,17].…”

Section: Introductionmentioning

confidence: 99%

Interleukin-37b Suppressed ILC2s in Children with Allergic Rhinitis

Zeng

Xiao

et al. 2023

Mediators of Inflammation

View full text Add to dashboard Cite

Background. Interleukin-37b is a fundamental inhibitor of innate and acquired immunity. Type 2 innate lymphoid cells (ILC2s) can secret type 2 cytokines and regulate allergic rhinitis (AR). However, the role of IL-37b in ILC2s in children with AR was not clear. Methods. We recruited 15 AR children and controls. The serum IL-37b levels and its relation with the frequency and functional phenotype of ILC2s. The regulation of IL-37b on ILC2s proliferation and function was confirmed using flow cytometry and enzyme-linked immunosorbent assay (ELISA). The mRNA expression of IL-1R8, IL-18Rα, and ICOSL was examined using RCR. The change of IL-37b protein level in serum during subcutaneous allergen immunotherapy (SCIT) was determined by ELISA. Results. We have demonstrated that both of the frequencies of blood ILC2s, IL-5+ILC2s, and IL-13+ILC2s in AR children were elevated compared with controls. The serum protein level of IL-37b was downregulated in AR, and it was negatively related to the frequency of ILC2s, IL-5+ILC2s, and IL-13+ILC2s. IL-37b increased the mRNA levels of IL-1R8, IL-18Rα, and ICOSL expressed by ILC2s. IL-37b suppressed the proliferation of ILC2s and the secretion of IL-5 and IL-13 from ILC2s. Finally, we found that IL-37b was increased in AR children after 3 years’ SLIT, especially in the good response group. Conclusion. Our findings highlight the role of IL-37b in the suppression of ILC2s and establish a new therapeutic target in AR.

show abstract

“… 27 IL-33 mediates microglia synaptic phagocytosis in central nervous system development. 28 Targeted inhibition of IL-36 signaling is used to treat pustular psoriasis 29 and both IL-37 and IL-38 suppress allergic disease, with the former binding maternal anti-alopecia homolog 3 and entering the nucleus to affect gene transcription, 30 and the latter antagonizing the ERK1/2 and NF-κB pathways and upregulating host defense genes. 31 The interleukin-1 family has been linked to CVD and IL-1α creates a pro-thrombotic microenvironment by inducing IL-6 production while IL-1β drives inflammation during atherosclerosis.…”

Section: Introductionmentioning

confidence: 99%

Progress of Research into the Interleukin-1 Family in Cardiovascular Disease

Wu¹,

Luo²,

Zheng³

2022

JIR

View full text Add to dashboard Cite

Inflammatory factors, such as the IL-1 family, are generally acknowledged to be involved in systemic diseases and IL-1α and IL-1β, in particular, have been linked to cardiovascular disease with IL-18, IL-33, IL-36, IL-37 and IL-38 yet to be explored. The current review aims to summarize mechanisms of IL-18, IL-33, IL-36, IL-37 and IL-38 in myocardial infarction, hypertension, arrhythmia, valvular disease and aneurysm and to explore the potential for cardiovascular disease treatment strategies and discuss future directions for prevention and treatment.

show abstract

Insight into interleukin-37: The potential therapeutic target in allergic diseases

Cited by 13 publications

References 114 publications

Serum Levels of IL-37 and Correlation with Inflammatory Cytokines and Clinical Outcomes in Patients with Coronary Artery Disease

Serum Levels of IL-37 and Correlation with Inflammatory Cytokines and Clinical Outcomes in Patients with Coronary Artery Disease

Interleukin-37b Suppressed ILC2s in Children with Allergic Rhinitis

Progress of Research into the Interleukin-1 Family in Cardiovascular Disease

Contact Info

Product

Resources

About